[Randomized trial of two administration schedule of bonephos (Clodronate) in patients with painful bone metastasis]. / Randomizirovannoe issledovanie dvukh skhem vvedeniia bonefosa (Klodronata) u bol'nykh s metastazami v kosti soprovozhdaiushchimisia bol'iu.

A randomized study of two intravenous schedules of Clodronate showed that a single 4-hour infusion of 1500 mg Clodronate proved significantly more effective than the traditional 2 hours infusion of 300 mg during 5 days. The regimen may prove preferable in therapy of patients with painful bone metastases.

[Treatment of lung metastasis in patients with soft-tissue sarcoma]. / Lechenie legochnykh metastazov u bol'nykh sarkomami miagkikh tkanei.

The study group included 104 patients with soft-tissue sarcoma and metastases into the lung, treated at the Institute Clinic in 1960-1992. Surgery for lung metastasis was given to 10 and chemotherapy-to 48 patients; the remaining 48 cases received treatment for symptoms only. Overall 5-year survival was 13.5% (after surgery-30.0%; chemotherapy-19.1%). All the 46 patients treated for symptoms died within two years after detection of lung metastasis. Chemotherapy proved effective in the treatment of multiple metastasis when detected shortly after removal of the first lesion.

[Use of adriamycin in the treatment of metastatic breast cancer]. / Lechenie metastaticheskikh form raka molochnoi zhelezy s ispol'zovaniem adriamitsina.

Adriamycin (alone and as a component of FAC scheme) should be administered to patients with disseminated breast cancer resistant to cytostatic drugs. This treatment is followed by remission and arrests the process for an average of 9 months (in some cases up to 30 months). Mean doses of 30-40 mg should be given to outpatients on days 1 and 8 of each course, with intervals between courses being 21-28 days. No apparent side-effects are observed. The total dose should be as high as 450-550 mg. Adjuvant antiestrogen treatment (tamoxifen) should be given to pre- and menopausal patients.

[Comparative evaluation of the results of mono- and polychemotherapy of disseminated forms of breast cancer using the CMFVP program and anthracycline antibiotics (carminomycin and adriamycin)]. / Sravnitel'naia otsenka rezul'tatov mono- i polikhimioterapii disseminirovannykh form raka molochnoi zhelezy s ispol'zovaniem programmy SMFVP i antratsiklinovykh antibiotikov (karminomitsina, adriamitsina).

A total of 203 out patients with disseminated cancer of the mammary glands subjected to chemotherapy were followed up. Of these, 44 patients were treated according to the CMFVP program, 66 were subjected to monochemotherapy with carminomycin, 42 were treated with combinations of carminomycin and dibromdulcytol, 14 patients received monochemotherapy with adriamycin and 37 polychemotherapy according to the scheme of fluorouracil + adriamycin + cyclophosphamide. In addition to the early-demonstrated efficacy of adriamycin and the Cooper scheme, the comparative estimation of the treatment programs showed that carminomycin, a new antitumor antibiotic made in the USSR, had an obvious activity when used alone or in combination with dibromdulcytol, an alkylating agent, in the treatment of primary extended forms, relapses and metastases of mammary tumors. The data indicate that wide use of carminomycin which is comparatively low toxic is advisable in the treatment of disseminated cancer of the mammary gland.

[Results of a clinical study of carminomycin in primary disseminated forms, recurrences and metastases of breast cancer]. / Rezul'taty klinicheskogo izucheniia karminomitsina pri pervichno-rasprostranennykh formakh, retsidivakh i metastazakh raka molochnoi zhelezy.

A more than 50% regression of tumor was observed in 19% of 64 patients treated with carminomycin for advanced primary breast cancer, its recurrences and metastases. A clinically-significant effect of treatment was recorded in 42%, while tumor process was arrested for at least 3-4 months in 37% of cases. The index of more than 50% regression of tumor rose to 28% in a group of 27 patients, following repeated courses of the drug. Only a slight toxic side--effect was observed, repeated courses included. Moderate leukopenia and a slight cardiotoxic effect were registered in 17%; phlebitis--in 12%. Carminomycin treatment should be recommended for advanced primary breast cancer, its recurrences an metastases, when other chemotherapeutic means fail to stop tumor process.

[Characteristics of the formation, course and outcome of lymphogranulomatous caverns in the lungs]. / Nekotorye osobennosti formirovaniia, techeniia i iskhoda limfogranulematoznykh kavern v legkikh.

Clinico-roentgenological manifestations of specific destructive lesions in the lung in cases of Hodgkin's disease are described. The authors' findings suggest that disintegration focus formation is determined by duration of diseases, rapid regression of specific lesion of the lung as a result of therapy and suppression of reparative regeneration of lung tissue by corticosteroids and possibly, cytostatic drugs. However, a course of cytostatic therapy eventually resulted in the regression of lung tissue alterations and dissolution of disintegration cavities in most cases.